Exelixis, Inc. EXEL
EXEL among the 162 companies we cover
Where it stands · the better end on the right. The band holds the middle half; the line is the median.
EXEL and 9 peers, year by year
The 9 Health care companies closest to EXEL in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.
Choose the peers
| Company | Year | Revenue | Sales growth | Gross margin | Operating margin | Net margin | FCF margin | Return on equity | Debt / equity |
|---|---|---|---|---|---|---|---|---|---|
| EXEL Exelixis, Inc. | FY2025 | $2.3B | +7.0% | - | 37.6% | 33.7% | 37.7% | 36.2% | - |
| MRNA Moderna | FY2025 | $1.9B | −39.9% | - | −158.1% | −145.2% | −106.2% | −32.6% | 0.07 |
| PRVA Privia Health Group, Inc. | FY2025 | $2.1B | +22.3% | - | 1.6% | 1.1% | - | 3.1% | - |
| QDEL QuidelOrtho Corp | FY2025 | $2.7B | −1.9% | - | −33.7% | −41.5% | −3.0% | −58.9% | 1.40 |
| RDNT RadNet, Inc. | FY2025 | $2.0B | +11.5% | - | 3.0% | −0.9% | - | −1.7% | 1.00 |
| RPRX Royalty Pharma plc | FY2025 | $2.4B | +5.1% | - | 65.6% | 32.4% | - | 7.9% | 0.92 |
| CON Concentra Group Holdings Parent, Inc. | FY2025 | $2.2B | +13.9% | - | 15.4% | 7.7% | 9.1% | 42.3% | 4.00 |
| CHE Chemed Corp | FY2025 | $2.5B | +4.1% | - | 13.4% | 10.5% | 12.9% | 27.1% | - |
| ENOV Enovis CORP | FY2025 | $2.2B | +6.7% | 59.8% | −50.0% | −52.7% | 0.9% | −79.5% | 0.87 |
| TFX Teleflex Inc | FY2025 | $2.0B | +17.2% | 56.2% | 5.9% | −45.4% | 0.1% | −29.0% | 0.85 |
Each company, year by year
Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2016 to FY2025 · 10-K XBRL
Who rewrote the most
Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before
Revenue, FY2016 to FY2025
Revenue as reported in the 10-K.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | $191.5M | $452.5M | $853.8M | $967.8M | $987.5M | $1.4B | $1.6B | $1.8B | $2.2B | $2.3B |
| MRNA Dec | $108.4M | $205.8M | $135.1M | $60.2M | $803.0M | $18.5B | $19.3B | $6.8B | $3.2B | $1.9B |
| PRVA Dec | - | - | - | $786.4M | $817.1M | $966.2M | $1.4B | $1.7B | $1.7B | $2.1B |
| QDEL Dec | - | - | - | - | $1.7B | $1.7B | $3.3B | $3.0B | $2.8B | $2.7B |
| RDNT Dec | $884.5M | $922.2M | $975.1M | $1.2B | $1.1B | $1.3B | $1.4B | $1.6B | $1.8B | $2.0B |
| RPRX Dec | - | - | $1.8B | $1.8B | $2.1B | $2.3B | $2.2B | $2.4B | $2.3B | $2.4B |
| CON Dec | - | - | - | - | - | - | $1.7B | $1.8B | $1.9B | $2.2B |
| CHE Dec | $1.6B | $1.7B | $1.8B | $1.9B | $2.1B | $2.1B | $2.1B | $2.3B | $2.4B | $2.5B |
| ENOV Dec | $3.2B | $3.3B | $3.7B | $3.3B | $1.1B | $1.4B | $1.6B | $1.7B | $2.1B | $2.2B |
| TFX Dec | $1.9B | $2.1B | $2.4B | $2.6B | $2.5B | $2.8B | $2.8B | $1.7B | $1.7B | $2.0B |
| Peer median | $1.6B | $1.7B | $1.8B | $1.8B | $1.4B | $1.9B | $2.1B | $1.8B | $2.1B | $2.2B |
Sales growth, FY2016 to FY2025
Revenue against the fiscal year before.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | - | +136% | +88.7% | +13.3% | +2.0% | +45.3% | +12.3% | +13.6% | +18.5% | +7.0% |
| MRNA Dec | - | +89.9% | −34.4% | −55.4% | n/m | n/m | +4.3% | −64.4% | −52.7% | −39.9% |
| PRVA Dec | - | - | - | - | +3.9% | +18.3% | +40.4% | +22.2% | +4.7% | +22.3% |
| QDEL Dec | - | - | - | - | - | +2.2% | +92.3% | −8.2% | −7.2% | −1.9% |
| RDNT Dec | +9.3% | +4.3% | +5.7% | +18.4% | −7.1% | +22.7% | +8.7% | +13.0% | +13.2% | +11.5% |
| RPRX Dec | - | - | - | +1.1% | +17.0% | +7.9% | −2.3% | +5.2% | −3.9% | +5.1% |
| CON Dec | - | - | - | - | - | - | - | +6.6% | +3.4% | +13.9% |
| CHE Dec | +2.2% | +5.7% | +7.0% | +7.0% | +4.2% | −5.5% | −4.7% | +9.4% | +7.4% | +4.1% |
| ENOV Dec | −7.2% | +3.6% | +13.2% | +51.7% | −7.7% | +27.3% | +9.6% | +9.2% | +23.5% | +6.7% |
| TFX Dec | +3.2% | +14.9% | +14.1% | +6.0% | −2.2% | +10.7% | −0.7% | +6.6% | −0.8% | +17.2% |
| Peer median | +2.7% | +5.7% | +7.0% | +6.5% | +0.8% | +10.7% | +6.5% | +6.6% | +3.4% | +6.7% |
Gross margin, FY2016 to FY2025
Gross profit / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | - | - | - | - | - | - | - | - | - | - |
| MRNA Dec | - | - | - | - | - | - | - | - | - | - |
| PRVA Dec | - | - | - | - | - | - | - | - | - | - |
| QDEL Dec | - | - | - | - | - | - | - | - | - | - |
| RDNT Dec | - | - | - | - | - | - | - | - | - | - |
| RPRX Dec | - | - | - | - | - | - | - | - | - | - |
| CON Dec | - | - | - | - | - | - | - | - | - | - |
| CHE Dec | - | - | - | - | - | - | - | - | - | - |
| ENOV Dec | 31.2% | 20.3% | 19.9% | 42.1% | 53.9% | 54.5% | 55.6% | 58.0% | 56.0% | 59.8% |
| TFX Dec | 53.3% | 54.6% | 53.2% | 54.3% | 52.2% | 55.2% | 54.9% | 60.7% | 61.0% | 56.2% |
| Peer median | - | - | - | - | - | - | - | - | - | - |
Operating margin, FY2016 to FY2025
Operating income / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | −14.7% | 36.7% | 51.4% | 38.2% | 11.1% | 20.0% | 12.5% | 9.3% | 27.9% | 37.6% |
| MRNA Dec | −206.4% | −130.9% | −306.0% | −906.8% | −95.0% | 72.0% | 48.9% | −61.9% | −121.9% | −158.1% |
| PRVA Dec | - | - | - | 2.0% | 3.1% | −22.5% | −1.4% | 1.2% | 1.0% | 1.6% |
| QDEL Dec | - | - | - | - | 63.8% | 53.3% | 25.8% | 4.6% | −70.5% | −33.7% |
| RDNT Dec | 4.4% | 5.4% | 3.2% | 6.1% | 3.3% | 6.3% | 3.2% | 6.1% | 5.7% | 3.0% |
| RPRX Dec | - | - | 76.0% | 144.6% | 75.2% | 62.5% | 13.7% | 63.4% | 57.1% | 65.6% |
| CON Dec | - | - | - | - | - | - | 15.0% | 15.6% | 16.0% | 15.4% |
| CHE Dec | 11.3% | 6.8% | 13.7% | 13.3% | 18.7% | 16.0% | 16.1% | 15.0% | 15.1% | 13.4% |
| ENOV Dec | 7.4% | 4.1% | 4.1% | 6.1% | −5.9% | −4.4% | −4.6% | −3.8% | −36.8% | −50.0% |
| TFX Dec | 17.1% | 17.3% | 13.1% | 16.5% | 16.7% | 22.4% | 17.9% | 15.1% | 6.1% | 5.9% |
| Peer median | 7.4% | 5.4% | 8.6% | 6.1% | 10.0% | 19.2% | 15.0% | 6.1% | 5.7% | 3.0% |
Net margin, FY2016 to FY2025
Net income / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | −36.7% | 34.1% | 80.8% | 33.2% | 11.3% | 16.1% | 11.3% | 11.4% | 24.0% | 33.7% |
| MRNA Dec | −199.5% | −124.3% | −284.8% | −853.7% | −93.0% | 66.1% | 43.4% | −68.8% | −110.0% | −145.2% |
| PRVA Dec | - | - | - | 1.0% | 3.8% | −19.5% | −0.6% | 1.4% | 0.8% | 1.1% |
| QDEL Dec | - | - | - | - | 48.8% | 41.5% | 16.8% | −0.3% | −73.7% | −41.5% |
| RDNT Dec | 0.8% | 0.0% | 3.3% | 1.3% | −1.4% | 1.9% | 0.7% | 0.2% | 0.2% | −0.9% |
| RPRX Dec | - | - | 76.8% | 129.4% | 45.9% | 27.1% | 1.9% | 48.2% | 37.9% | 32.4% |
| CON Dec | - | - | - | - | - | - | 9.7% | 9.8% | 8.8% | 7.7% |
| CHE Dec | 6.9% | 5.9% | 11.5% | 11.3% | 15.4% | 12.6% | 11.7% | 12.0% | 12.4% | 10.5% |
| ENOV Dec | 4.0% | 4.6% | 3.8% | −15.9% | 3.8% | 5.0% | −0.9% | −1.9% | −39.2% | −52.7% |
| TFX Dec | 12.7% | 7.1% | 8.2% | 17.8% | 13.2% | 17.3% | 13.0% | 20.8% | 4.1% | −45.4% |
| Peer median | 4.0% | 4.6% | 6.0% | 1.3% | 8.5% | 14.9% | 9.7% | 1.4% | 0.8% | −0.9% |
Free cash flow, FY2016 to FY2025
Cash from operations minus capital spending.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | $204.6M | $144.5M | $382.4M | $514.1M | $178.6M | $346.6M | $334.9M | $292.9M | $671.5M | $875.8M |
| MRNA Dec | $33.6M | −$389.9M | −$436.6M | −$491.0M | $2.0B | $13.3B | $4.6B | −$3.8B | −$4.1B | −$2.1B |
| PRVA Dec | - | - | - | $18.6M | $38.5M | $54.5M | $47.1M | $80.7M | - | - |
| QDEL Dec | - | - | - | - | $564.8M | $513.1M | $744.4M | $70.9M | −$112.1M | −$83.0M |
| RDNT Dec | $32.4M | $80.9M | $44.6M | $30.2M | - | - | - | - | - | - |
| RPRX Dec | - | - | - | - | - | - | - | - | - | - |
| CON Dec | - | - | - | - | - | - | $228.4M | $169.4M | $210.3M | $197.1M |
| CHE Dec | $95.6M | $98.2M | $234.3M | $248.2M | $430.5M | $249.9M | $252.6M | $273.4M | $368.0M | $325.5M |
| ENOV Dec | $183.7M | $150.0M | $156.7M | $5.5M | $187.2M | $251.9M | −$161.3M | $12.8M | −$67.2M | $19.9M |
| TFX Dec | $357.5M | $355.4M | $354.3M | $334.4M | $346.4M | $580.5M | $263.6M | $159.7M | $211.4M | $1.4M |
| Peer median | $95.6M | $98.2M | $156.7M | $24.4M | $388.5M | $382.5M | $252.6M | $80.7M | $71.6M | $10.7M |
FCF margin, FY2016 to FY2025
Free cash flow / revenue.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | 106.9% | 31.9% | 44.8% | 53.1% | 18.1% | 24.2% | 20.8% | 16.0% | 31.0% | 37.7% |
| MRNA Dec | 31.0% | −189.4% | −323.3% | −815.5% | 244.0% | 72.2% | 23.8% | −55.9% | −125.3% | −106.2% |
| PRVA Dec | - | - | - | 2.4% | 4.7% | 5.6% | 3.5% | 4.9% | - | - |
| QDEL Dec | - | - | - | - | 34.0% | 30.2% | 22.8% | 2.4% | −4.0% | −3.0% |
| RDNT Dec | 3.7% | 8.8% | 4.6% | 2.6% | - | - | - | - | - | - |
| RPRX Dec | - | - | - | - | - | - | - | - | - | - |
| CON Dec | - | - | - | - | - | - | 13.2% | 9.2% | 11.1% | 9.1% |
| CHE Dec | 6.1% | 5.9% | 13.1% | 12.8% | 20.7% | 11.7% | 11.8% | 12.1% | 15.1% | 12.9% |
| ENOV Dec | 5.8% | 4.5% | 4.3% | 0.2% | 16.7% | 17.7% | −10.3% | 0.7% | −3.2% | 0.9% |
| TFX Dec | 19.1% | 16.6% | 14.5% | 12.9% | 13.7% | 20.7% | 9.4% | 9.3% | 12.4% | 0.1% |
| Peer median | 6.1% | 5.9% | 4.6% | 2.5% | 18.7% | 19.2% | 11.8% | 4.9% | 3.9% | 0.5% |
Return on equity, FY2016 to FY2025
Net income / shareholders' equity at the year end.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | −78.6% | 54.1% | 53.6% | 19.0% | 5.9% | 10.5% | 7.3% | 9.2% | 23.2% | 36.2% |
| MRNA Dec | n/m | n/m | −25.1% | −43.7% | −29.2% | 86.3% | 43.7% | −34.0% | −32.7% | −32.6% |
| PRVA Dec | - | - | - | 7.7% | 21.3% | −44.1% | −1.7% | 4.1% | 2.3% | 3.1% |
| QDEL Dec | - | - | - | - | 60.8% | 36.5% | 11.1% | −0.2% | −68.8% | −58.9% |
| RDNT Dec | 13.9% | 0.1% | 25.4% | 9.7% | −9.0% | 10.8% | 3.2% | 0.5% | 0.3% | −1.7% |
| RPRX Dec | - | - | 30.3% | 38.2% | 9.9% | 6.0% | 0.4% | 11.3% | 8.3% | 7.9% |
| CON Dec | - | - | - | - | - | - | 17.0% | 15.5% | 60.4% | 42.3% |
| CHE Dec | 20.7% | 18.2% | 34.8% | 30.3% | 35.4% | 43.1% | 31.3% | 24.6% | 27.0% | 27.1% |
| ENOV Dec | 4.4% | 4.3% | 4.3% | −15.3% | 1.2% | 1.6% | −0.4% | −1.0% | −32.2% | −79.5% |
| TFX Dec | 11.1% | 6.3% | 7.9% | 15.5% | 10.1% | 12.9% | 9.0% | 8.0% | 1.6% | −29.0% |
| Peer median | 12.5% | 5.3% | 16.6% | 9.7% | 10.0% | 11.9% | 9.0% | 4.1% | 1.6% | −1.7% |
Debt / equity, FY2016 to FY2025
Total debt / shareholders' equity at the year end.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | 2.12 | 0.00 | - | - | - | - | - | - | - | - |
| MRNA Dec | - | - | - | - | - | - | - | - | 0.00 | 0.07 |
| PRVA Dec | - | - | - | - | 0.23 | 0.08 | 0.00 | - | - | - |
| QDEL Dec | - | - | - | - | - | 0.00 | 0.54 | 0.48 | 0.83 | 1.40 |
| RDNT Dec | 11.78 | 9.35 | 5.57 | 4.92 | 3.94 | 3.30 | 2.56 | 1.32 | 1.13 | 1.00 |
| RPRX Dec | - | - | - | 1.02 | 0.59 | 0.69 | 0.75 | 0.61 | 0.74 | 0.92 |
| CON Dec | - | - | - | - | - | - | - | 0.00 | 5.37 | 4.00 |
| CHE Dec | 0.21 | 0.19 | 0.15 | 0.12 | - | 0.30 | 0.12 | - | - | - |
| ENOV Dec | 0.45 | 0.30 | 0.37 | 0.67 | 0.63 | 0.45 | 0.08 | 0.14 | 0.52 | 0.87 |
| TFX Dec | 0.48 | 0.96 | 0.85 | 0.64 | 0.74 | 0.49 | 0.43 | 0.41 | 0.39 | 0.85 |
| Peer median | 0.46 | 0.63 | 0.61 | 0.67 | 0.63 | 0.45 | 0.43 | 0.45 | 0.74 | 0.92 |
EPS (diluted), FY2016 to FY2025
Diluted earnings per share, on today's share count after splits.
| Company | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL Jan | −$0.28 | $0.49 | $2.21 | $1.02 | $0.35 | $0.72 | $0.56 | $0.65 | $1.76 | $2.78 |
| MRNA Dec | −$3.79 | −$4.18 | −$4.95 | −$1.55 | −$1.96 | $28.29 | $20.12 | −$12.33 | −$9.28 | −$7.26 |
| PRVA Dec | - | - | - | $0.09 | $0.33 | −$1.83 | −$0.08 | $0.19 | $0.11 | $0.18 |
| QDEL Dec | - | - | - | - | $18.60 | $16.43 | $9.56 | −$0.15 | −$30.54 | −$16.69 |
| RDNT Dec | $0.15 | $0.00 | $0.66 | $0.29 | −$0.29 | $0.46 | $0.17 | $0.05 | $0.04 | −$0.25 |
| RPRX Dec | - | - | - | - | $1.32 | $1.49 | $0.10 | $2.53 | $1.91 | $1.78 |
| CON Dec | - | - | - | - | - | - | $1.60 | $1.73 | $1.46 | $1.30 |
| CHE Dec | $6.48 | $5.86 | $12.23 | $13.31 | $19.48 | $16.85 | $16.53 | $17.93 | $19.89 | $18.34 |
| ENOV Dec | $3.12 | $3.66 | $3.48 | −$11.67 | $0.93 | $1.40 | −$0.25 | −$0.61 | −$14.93 | −$20.75 |
| TFX Dec | $4.98 | $3.27 | $4.29 | $9.80 | $7.09 | $10.23 | $7.68 | $7.53 | $1.48 | −$20.25 |
| Peer median | $3.12 | $3.27 | $3.48 | $0.19 | $1.12 | $5.86 | $1.60 | $0.19 | $0.11 | −$0.25 |
Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out EXEL and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more
Sources
Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.
Also
Financials: EXEL's own statements, year by year. Compare: the whole peer group on one page.
Work with it
Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/EXEL/export.csv") into a cell.